Overview

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Status:
Completed

Trial end date:
2016-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Carboplatin
Doxorubicin
Gemcitabine
Iniparib
Irinotecan
Liposomal doxorubicin
Paclitaxel
Topotecan